BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: Implications for monitoring and management

Blood

Volumn 119, Issue 18, 2012, Pages 4264-4271

  Branford, Susan ^a,b   Yeung, David T ^b,c   Prime, Jodi A ^a   Choi, Soo Young ^d   Bang, Ju Hee ^d   Park, Jin Eok ^d   Kim, Dong Wook ^d   Ross, David M ^b,c,e   Hughes, Timothy P ^b,c  

^a Rundle Mall ^*  (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c CENTRE FOR CANCER BIOLOGY   (Australia)

^d The Catholic University of Korea   (South Korea)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IMATINIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; FOLLOW UP; GENE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN FOLDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

EID: 84860752177     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-393041     Document Type: Article

References (50)

1. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
2. Branford S, Rudzki Z, Parkinson I, et al. Realtime quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104(9):2926-2932. (Pubitemid 39434981)
3. Wang L, Knight K, Lucas C, Clark RE. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica. 2006;91(2):235-239.
4. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007;13(20): 6136-6143. (Pubitemid 350075073)
5. Marin D, Khorashad JS, Foroni L, et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? Br J Haematol. 2009;145(3):373-375.
6. Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14): 2381-2388.
7. O'Brien S. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, Version 2.2012. http://wwwnccnorg/professionals/physician. Accessed July 11, 2011.
8. Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood. 2009;114(13):2598-2605.
9. Lin F, van Rhee F, Goldman JM, Cross NC. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood. 1996; 87(10):4473-4478. (Pubitemid 26152290)
10. Ollila DW, Stern SL, Morton DL. Tumor doubling time: A selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol. 1998;69(4): 206-211. (Pubitemid 29024563)
11. Bidart J-M, Thuillier F, Augereau C, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem. 1999; 45(10):1695-1707. (Pubitemid 29477325)
12. Mano A, Godinho I, Falcao AC. CA 125 half-life breakpoint between a "good" and "poor" prognosis in patients with ovarian cancer. Int J Gynaecol Obstet. 2005;88(3):333-335. (Pubitemid 40283618)
13. Meijer JA, le Cessie S, van den Hout WB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: A structured meta-analysis. Clin Endocrinol (Oxf). 2010;72(4):534-542.
14. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. 2004;104(7):2204-2205. (Pubitemid 39297882)
15. Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases. Am J Hematol. 2004;76(3):275-278. (Pubitemid 38828850)
16. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005; 435(7046):1267-1270. (Pubitemid 40943094)
17. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood. 2009;113(22):5401-5411.
18. Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011; 117(14):3733-3736.
19. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432. (Pubitemid 37211057)
20. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112(10):3965-3973.
21. Yeung DT, Osborn M, White DL, et al. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: Interim results from the TIDEL-II trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):209.
22. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24(10):1719-1724.
23. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28(3):424-430.
24. Branford S, Fletcher L, Cross NCP, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-3338.
25. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107(3):587-599.
26. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99(9):3472-3475. (Pubitemid 34525335)
27. Hughes TP, Hochhaus A, Branford S, et al. Longterm prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116(19):3758-3765.
28. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
29. Goh H-G, Choi S-Y, Bang J-He, et al. Discontinuation of imatinib therapy in chronic myeloid leukemia patients with sustained complete molecular response4.5 (CMR4.5) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):2763.
30. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115(2):198-205.
31. Ernst T, Erben P, Muller MC, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. 2008;93(2):186-192. (Pubitemid 351397706)
32. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276-283. (Pubitemid 36759665)
33. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylateresistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(varphi)-LMC GROUP). Leukemia. 2006;20(6):1061-1066. (Pubitemid 43797298)
34. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphiapositive patients: By the GIMEMAWorking Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374-7379. (Pubitemid 46095411)
35. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008; 26(29):4806-4813.
36. Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(-) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009;114(26):5271-5278.
37. Skaggs BJ, Gorre ME, Ryvkin A, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A. 2006;103(51):19466-19471. (Pubitemid 46026054)
38. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008; 112(1):53-55.
39. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441-453. (Pubitemid 46823444)
40. Gruber FX, Ernst T, Porkka K, et al. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. Leukemia. 2012;26(1):172-177.
41. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med. 2006;354(24): 2531-2541. (Pubitemid 43882349)
42. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354(24):2542-2551. (Pubitemid 43882350)
43. Guilhot F, Apperley J, Kim D-W, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109(10):4143-4150. (Pubitemid 46743375)
44. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant acceleratedphase chronic myelogenous leukemia. Blood. 2008;111(4):1834-1839. (Pubitemid 351451490)
45. Muller MC, Cortes JE, Kim D-W, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114(24): 4944-4953.
46. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27(25):4204-4210.
47. Woo V, Shestakova MV, Orskov C, Ceriello A. Targets and tactics: The relative importance of HbA, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes. Int J Clin Pract. 2008;62(12):1935-1942.
48. Muller MC, Cross NCP, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23(11):1957-1963.
49. Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20(11):1925-1930. (Pubitemid 44614879)
50. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497. (Pubitemid 41127293)